Mark J. Ratain to Mutation
This is a "connection" page, showing publications Mark J. Ratain has written about Mutation.
Connection Strength
0.389
-
EGFR pharmacogenomics: the story continues to mutate and evolve. Am J Pharmacogenomics. 2005; 5(2):137-9.
Score: 0.116
-
Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib. Br J Clin Pharmacol. 2021 11; 87(11):4313-4322.
Score: 0.090
-
A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection. PLoS One. 2013; 8(5):e62989.
Score: 0.052
-
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
Score: 0.043
-
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6788-95.
Score: 0.035
-
Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer. 2002 Mar; 38(5):639-44.
Score: 0.024
-
Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. Eur Urol Focus. 2019 05; 5(3):416-424.
Score: 0.018
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
Score: 0.011